Fully Featured Yet Simplified Phase 1 IRT Solution
Traditional thinking was that Phase 1 clinical studies were small and simple, making randomization and clinical supply management technology too expensive and resource intensive for the size and scope of the study. However, with the growing trend towards personalized medicine and gene therapies, creative trial designs, expanded protocol complexity, and increasing number of protocol amendments throughout a trial, today’s Phase 1 clinical trials can be even more complex than Phase 2 or 3 trials.
Download the case study to see how YPrime’s fully featured yet simplified IRT enterprise solution allowed the sponsor to configure their randomization and supply parameters, giving them the ability to better manage dosing scenarios, visit schedules, and drug supply for complex oncology studies.
Complete the form below to download the case study.